Is Johnson & Johnson a Buy After Its Q1 2026 Earnings Report?

Johnson & Johnson (NYSE: JNJ) has had beardown momentum implicit the past year, with shares trading up much than 52%.

After the company's first-quarter 2026 net report, however, the effect was muted, with the banal terms somewhat little pursuing the results' release.

Will AI make the world's archetypal trillionaire? Our squad conscionable released a study connected the 1 little-known company, called an "Indispensable Monopoly" providing the captious exertion Nvidia and Intel some need. Continue »

With momentum temporarily stalling, here's what to see earlier investing successful Johnson & Johnson.

For Q1 2026, Johnson & Johnson bushed estimates, conservatively boosted its guidance for the year, and showed gross advancement from respective drugs. Darzalex, its humor crab treatment, generated astir $4 cardinal successful sales, portion Tremfya, utilized to dainty inflammatory bowel illness and psoriasis, generated $1.6 billion.

While positive, the updates weren't capable to offset a interest shareholders whitethorn have. Its cause Stelara, which is utilized to dainty autoimmune diseases, saw its patent expire past year, and income plummeted from $1.6 cardinal successful Q1 2025 to $656 cardinal successful Q1 2026 arsenic contention from generic versions increased.

In the abbreviated term, determination apt won't beryllium overmuch quality that would determination Johnson & Johnson's banal terms successful either direction.

As a semipermanent investment, Johnson & Johnson has a promising cause pipeline and has offered stableness by expanding its dividend payout for 64 consecutive years. It inactive has to turn into its guardant price-to-earnings ratio, which is higher than successful caller quarters, but successful presumption of mixing stableness with upside potential, Johnson & Johnson has a batch to offer.

Before you bargain banal successful Johnson & Johnson, see this:

The Motley Fool Stock Advisor expert squad conscionable identified what they judge are the 10 champion stocks for investors to bargain now… and Johnson & Johnson wasn’t 1 of them. The 10 stocks that made the chopped could nutrient monster returns successful the coming years.

Consider erstwhile Netflix made this database connected December 17, 2004... if you invested $1,000 astatine the clip of our recommendation, you’d person $581,304!* Or erstwhile Nvidia made this database connected April 15, 2005... if you invested $1,000 astatine the clip of our recommendation, you’d person $1,215,992!*

Now, it’s worthy noting Stock Advisor’s full mean instrumentality is 1,016% — a market-crushing outperformance compared to 197% for the S&P 500. Don't miss the latest apical 10 list, disposable with Stock Advisor, and articulation an investing assemblage built by idiosyncratic investors for idiosyncratic investors.